Shots:

• NICE has issued a positive Final Appraisal Document which recommends Sunosi (75/150mg, qd) as an option treatment for adults with EDS caused by narcolepsy with/out cataplexy. The therapy will be available in England and Wales
• The recommendation is based on the P-III TONES studies to evaluate Sunosi vs PBO in adults patients with EDS. The results demonstrated a clinical effectiveness and safety profile of solriamfetol in patients with narcolepsy & maintain its effect after 6mos. of treatment
• Solriamfetol is dual-acting dopamine and noradrenaline reuptake inhibitor & is designed to improve wakefulness and reduce EDS in adult patients with narcolepsy

  Ref: Jazz  | Image: Jazz